Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

• Published in: Clinical cancer research Vol. 31; no. 6; pp. 965 - 974
• Main Authors: Tsimberidou, Apostolia M., Vining, David J., Arora, Sukeshi P., de Achaval, Sofia, Larson, Jeffrey, Kauh, John, Cartwright, Carrie, Avritscher, Rony, Alibhai, Imran, Tweardy, David J., Kaseb, Ahmed O.
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 17.03.2025
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - therapeutic use; Biological Agents & Therapies; Clinical Trials: Targeted Therapy; Clinical-stage Research; Female; Humans; Male; Middle Aged; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; STAT3 Transcription Factor - antagonists & inhibitors; Translational Research; Treatment Outcome

Signal transducer and activator of transcription 3 is a transcription factor that is essential for the survival and immune sequestration of cancer cells. We conducted a phase I study of TTI-101, a first-in-class, selective small-molecule inhibitor of signal transducer and activator of transcription...